# m2m Imaging

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/m2m-imaging

- Industry: Medical Devices & Equipment
- Headquarters: Cleveland, US
- Website: www.m2mimaging.com
- Total disclosed funding: $3.5M
- Latest round: Series C (Oct 25, 2006)
- Investors on record: 1

## About

m2m Imaging Corp. specializes in advanced imaging technology, focusing on the development and manufacturing of hyperpolarizers and RF coils for magnetic resonance imaging (MRI), enhancing diagnostic capabilities in pulmonary health.m2m Imaging Corp. provides specialized imaging technology solutions. Founded in 1999 in Cleveland, US, the company was formed through a merger with Polarean Inc. The current CEO is Richard Hullihen, and the founder is Bastiaan Driehuys. The company has successfully completed 3 deals, with the most recent funding round occurring on January 21, 2008, when m2m Imaging raised USD 2.00 mn from investor Amphion Innovations, bringing the total amount raised to USD 2.00 mn.Polarean, formed from the merger of m2m Imaging and Polarean Inc., specializes in advanced imaging technology, primarily focusing on the development and manufacturing of Xenon 129 hyperpolarizers and custom RF coils for magnetic resonance imaging (MRI). Their flagship product, the Xenon 129 hyperpolarizer, enhances the MRI imaging process by increasing the signal strength of Xenon gas, which is utilized in pulmonary functional MRI to assess lung function and detect various pulmonary conditions. The custom RF coils developed by the company are tailored to optimize imaging quality and resolution in clinical and research settings. Polarean's products serve hospitals, research institutions, and medical imaging facilities, particularly in markets across North America and Europe. By combining innovative imaging technologies with clinical applications, the company aims to provide healthcare providers with critical tools for improving patient outcomes in pulmonary health.Polarean's business model primarily revolves around direct sales of its specialized imaging products to hospitals and research facilities, forming a B2B structure focused on clinical application. The company generates revenue through the sale of its Xenon 129 hyperpolarizers and custom RF coils, engaging in direct transactions with clients who require high-quality imaging solutions for pulmonary diagnostics. Pricing structures for these products are designed to reflect the advanced technology and customization involved, catering to the specific needs of healthcare providers. Orders are processed through standard procurement channels, with contracts detailing specifications and delivery timelines. The emphasis on direct sales promotes long-term partnerships with institutions aiming to enhance their imaging capabilities and improve patient care through innovative technology.The recent funding of USD 2.00 mn raised in January 2008 will be utilized to further support the development of new products and enhance market reach. Polarean is focusing on the design and launch of upgraded Xenon 129 hyperpolarizers, with plans for release in upcoming quarters. The company has strategic intentions to expand into new markets, particularly targeting regions in Europe where there is growing demand for advanced imaging solutions. These efforts are aimed at solidifying Polarean's presence in the healthcare imaging sector.

## Funding rounds

- Series C, Oct 25, 2006, $3.5M — Amphion Innovations

## Investors

- Amphion Innovations (https://capitalatlas.ai/funds/amphion-innovations) — Series C